E3 SUMO-protein ligase PIAS4 is one of several protein inhibitor of activated STAT (PIAS) proteins. It is also known as protein inhibitor of activated STAT protein gamma (PIASg or PIASy), and is an enzyme that in humans is encoded by the PIAS4gene.[1][2]
↑ 3.03.1Imoto, Seiyu; Sugiyama Kenji; Muromoto Ryuta; Sato Noriko; Yamamoto Tetsuya; Matsuda Tadashi (Sep 2003). "Regulation of transforming growth factor-beta signaling by protein inhibitor of activated STAT, PIASy through Smad3". J. Biol. Chem. United States. 278 (36): 34253–8. doi:10.1074/jbc.M304961200. ISSN0021-9258. PMID12815042.
Maruyama K, Sugano S (1994). "Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides". Gene. 138 (1–2): 171–4. doi:10.1016/0378-1119(94)90802-8. PMID8125298.
Suzuki Y, Yoshitomo-Nakagawa K, Maruyama K, et al. (1997). "Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library". Gene. 200 (1–2): 149–56. doi:10.1016/S0378-1119(97)00411-3. PMID9373149.
Nelson V, Davis GE, Maxwell SA (2001). "A putative protein inhibitor of activated STAT (PIASy) interacts with p53 and inhibits p53-mediated transactivation but not apoptosis". Apoptosis. 6 (3): 221–34. doi:10.1023/A:1011392811628. PMID11388671.
Gross M, Liu B, Tan J, et al. (2001). "Distinct effects of PIAS proteins on androgen-mediated gene activation in prostate cancer cells". Oncogene. 20 (29): 3880–7. doi:10.1038/sj.onc.1204489. PMID11439351.
Ohmine K, Ota J, Ueda M, et al. (2002). "Characterization of stage progression in chronic myeloid leukemia by DNA microarray with purified hematopoietic stem cells". Oncogene. 20 (57): 8249–57. doi:10.1038/sj.onc.1205029. PMID11781839.
Tan JA, Hall SH, Hamil KG, et al. (2002). "Protein inhibitors of activated STAT resemble scaffold attachment factors and function as interacting nuclear receptor coregulators". J. Biol. Chem. 277 (19): 16993–7001. doi:10.1074/jbc.M109217200. PMID11877418.
Subramanian L, Benson MD, Iñiguez-Lluhí JA (2003). "A synergy control motif within the attenuator domain of CCAAT/enhancer-binding protein alpha inhibits transcriptional synergy through its PIASy-enhanced modification by SUMO-1 or SUMO-3". J. Biol. Chem. 278 (11): 9134–41. doi:10.1074/jbc.M210440200. PMID12511558.
Dahle Ø, Andersen TØ, Nordgård O, et al. (2003). "Transactivation properties of c-Myb are critically dependent on two SUMO-1 acceptor sites that are conjugated in a PIASy enhanced manner". Eur. J. Biochem. 270 (6): 1338–48. doi:10.1046/j.1432-1033.2003.03504.x. PMID12631292.
Lee PS, Chang C, Liu D, Derynck R (2003). "Sumoylation of Smad4, the common Smad mediator of transforming growth factor-beta family signaling". J. Biol. Chem. 278 (30): 27853–63. doi:10.1074/jbc.M301755200. PMID12740389.
Chun TH, Itoh H, Subramanian L, et al. (2003). "Modification of GATA-2 transcriptional activity in endothelial cells by the SUMO E3 ligase PIASy". Circ. Res. 92 (11): 1201–8. doi:10.1161/01.RES.0000076893.70898.36. PMID12750312.
Imoto S, Sugiyama K, Muromoto R, et al. (2003). "Regulation of transforming growth factor-beta signaling by protein inhibitor of activated STAT, PIASy through Smad3". J. Biol. Chem. 278 (36): 34253–8. doi:10.1074/jbc.M304961200. PMID12815042.
Galleguillos D, Vecchiola A, Fuentealba JA, et al. (2004). "PIASgamma represses the transcriptional activation induced by the nuclear receptor Nurr1". J. Biol. Chem. 279 (3): 2005–11. doi:10.1074/jbc.M308113200. PMID14559918.
Gross M, Yang R, Top I, et al. (2004). "PIASy-mediated repression of the androgen receptor is independent of sumoylation". Oncogene. 23 (17): 3059–66. doi:10.1038/sj.onc.1207443. PMID14981544.
Zoumpoulidou G, Jones MC, Fernandez de Mattos S, et al. (2005). "Convergence of interferon-gamma and progesterone signaling pathways in human endometrium: role of PIASy (protein inhibitor of activated signal transducer and activator of transcription-y)". Mol. Endocrinol. 18 (8): 1988–99. doi:10.1210/me.2003-0467. PMID15155784.
Imoto S, Sugiyama K, Yamamoto T, Matsuda T (2004). "The RING domain of PIASy is involved in the suppression of bone morphogenetic protein-signaling pathway". Biochem. Biophys. Res. Commun. 319 (1): 275–82. doi:10.1016/j.bbrc.2004.04.161. PMID15158472.